Ref. | Patients (HCC) | Ethnicity | Blood Source | Controls | Measurements | Methodology | Positive Rate |
---|---|---|---|---|---|---|---|
Matsumura M et al., 1994 [22] | 33 | Japan | Hepatic Vein Inferior Vena Cava | HV (30) | AFP | RT-PCR | 52% |
Funaki N et al., 1995 [103] | 12 | Japan | Peripheral blood | HV (5) | AFP | RT-PCR | 71% |
Lemoine A et al., 1997 [24] | 20 | France | Pre, During Peripheral blood | 44 (IHC:2; LM: 25; LC: 13; HV: 2) | AFP | RT-PCR | 17% |
Matsumura M et al., 1999 [23] | 88 | Japan | Peripheral blood | NA | AFP | RT-PCR | 63% |
Wong IH et al., 2001 [25] | 84 | China | Pre, During, Post Peripheral blood | HV (53) | AFP ALB | RT-PCR | 55% |
Mou et al., 2002 [31] | 30 | China | Pre resection | HV (25) | MAGE1 MAGE3 | RT-PCR | 43% |
Witzigmann et al., 2002 [26] | 85 | Germany | Pre, During, Post Peripheral blood | 116 (OLT: 50; BLD: 39; HV: 27) | AFP | RT-PCR | 28% |
Cillo et al., 2004 [27] | 50 | Italy | Pre Resection Peripheral blood | 50 (HD: 6; OCD: 44) | AFP | RT-PCR | 40% |
Jeng et al., 2004 [28] | 81 | China | Pre, Post Resection Peripheral blood | 50 (HV: 30; HD: 69) | AFP | RT-PCR | 23% |
Kong et al., 2009 [29] | 343 | South Korea | Peripheral blood | NA | AFP hTERT | RT-PCR | 59% 14% |
Bahnassy AA et al., 2014 [33] | 120 | Egypt | Peripheral blood | 63 (CLD: 30; HV: 33) | MAGE1/3 CK19 CD133 | RT-PCR | 55% 73% 69% |
Choi GH et al., 2015 [34] | 81 | South Korea | Peripheral blood | 16 (LHD) | K19, CD44 | RT-PCT | 22% |
Jin JH et al., 2016 [30] | 72 | China | Peripheral blood | NA | AFP | RT-PCR | 59% |
Guo LM et al., 2017 [35] | 51 | China | Peripheral blood | 30 (LC: 10; HV: 20) | CTAs PLAC1 | RT-PCR | 70% |
Vona G et al., 2000 [36] | 7 | France | Peripheral blood | HV (8) | AFP | ISET RT-PCR | 42% |
Vona G et al., 2004 [104] | 44 | France | Peripheral blood | 107 (HV:38; HD: 20) | NA | ISET | 52% |
Morris KL et al., 2014 [37] | 52 | United Kingdom | Peripheral blood | No treatment | GPC3 | ISET CellSearch™ | 100% |
Fan J et al., 2011 [105] | 82 | China | Pre, Post resection | NA | NA | CellSearch™ | 68% |
Xu W et al., 2011 [44] | 85 | China | Pre resection | 71 (HD: 37; HV: 20; OCD: 14) | Hep Par 1 | CellSearch™ | 81% |
Schulze K et al., 2013 | 59 | Germany | Pre resection | HD (19) | AFP | CellSearch™ | 30% |
Sun YF et al., 2013 [41] | 123 | China | Pre, Post resection | NA | CD133 ABCG2 | CellSearch™ | 66% |
Mu H et al., 2014 [106] | 62 | China | Peripheral blood | 22 (CLD: 7; HV: 15) | ASGPR GPC3 | CellSearch™ | 90% 93% |
Guo W et al., 2014 [107] | 299 | China | Peripheral blood | 120 (HV: 71; BT: 24; CLD: 25) | EpCAM | CellSearch™ | 76% |
Kelley RK et al., 2015 [42] | 20 | Caucasian 55% Asian 35% American 10% | Peripheral blood | NA | NA | CellSearch™ | 40% |
Zhou Y et al., 2016 [108] | 49 | China | Peripheral blood | HV (50) | CD4 | CellSearch™ | 35% |
Felden JV et al., 2017 [109] | 61 | Germany | Peripheral blood | CLD (31) | NA | CellSearch™ | 15% |
Sun YF et al., 2017 [40] | 73 | China | Peripheral blood Portal Vein | NA | EpCAM | CellSearch™ | 68% |
Xu Wen et al., 2011 [44] | 85 | China | Peripheral blood | 37 (CLD) | Her-2 TP53 | Flow Cytometry | 81% |
Li YM et al., 2013 [49] | 60 | China | Peripheral blood | 30 (BT: 10; HV: 10; OLT: 10) | Twist Vimentin | Flow Cytometry | 76% |
Li J et al., 2014 [45] | 27 | China | Peripheral blood | 61 (OLT: 12; CLD:23; BT: 11; HV: 15) | ASGPR CPS1 P-CK | Flow Cytometry | 89% |
Liu HY et al., 2015 [46] | 32 | China | Peripheral blood | 77 (OLT: 17; CLD: 40; HV: 20) | ASGPR CPS1 | Flow Cytometry | 91% |
Liu ZX et al., 2016 [47] | 52 | China | Peripheral blood | HV (12) | EpCAM | Flow Cytometry | 57% |
Li J et al., 2016 [48] | 109 | China | Peripheral blood | NA | pERK pAkt | Flow Cytometry | 92% |
Shi J et al., 2016 [50] | 47 | China | Pre, Post Resection Peripheral blood | NA | EpCAM | Flow Cytometry | 100% |
Ogle LF et al., 2016 [51] | 69 | United Kingdom | Peripheral blood | 31 (HV: 15; CLD: 16) | Cytokeratin EpCAM | Flow Cytometry | 29% 18% |
Julich-Haertel H et al., 2017 [52] | 172 | Germany | Peripheral blood | 256 (CLD: 54; HV: 202) | EpCAM ASGPR1 taMRs | Flow Cytometry | 78% |
Zhang Yu et al., 2016 [55] | 36 | China | Peripheral blood | NA | CPS1 CD45 | CTC-Chip | 85% |
Kalinich M et al., 2016 [54] | 16 | United States | Peripheral blood | NA | Chip | CTC-Chip | 56% |
Wang S et al., 2016 [56] | 42 | China | Peripheral blood | NA | Chip | CTC-Chip | 61% |
Wang Z et al., 2017 [38] | 62 | China | Peripheral blood | NA | NA | CanPatroI™ System | 84% |
Chen J et al., 2017 [39] | 195 | China | Peripheral blood | NA | NA | CanPatroI™ System | 95% |